Atea Pharmaceuticals (AVIR) Common Equity (2019 - 2026)

Atea Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $233.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 43.15% year-over-year to $233.7 million; the TTM figure through Mar 2026 stood at $233.7 million (down 43.15% YoY), while the FY2025 annual figure was $275.4 million, down 37.24% from the prior year.
• Common Equity for Q1 2026 stood at $233.7 million, down from $275.4 million in the prior quarter.
• The five-year high for Common Equity was $679.9 million in Q1 2022, with the low at $233.7 million in Q1 2026.
• The 5-year median for Common Equity is $504.4 million (2024), against an average of $498.8 million.
• The sharpest annual moves came in 2022 and 2026: Common Equity rose 15.97% in 2022, then plunged 43.15% in 2026.
• Atea Pharmaceuticals' Common Equity stood at $640.6 million in 2022, then decreased by 13.33% to $555.2 million in 2023, then declined by 20.95% to $438.9 million in 2024, then sank by 37.24% to $275.4 million in 2025, then retreated by 15.15% to $233.7 million in 2026.
• Business Quant data shows AVIR's Common Equity at $233.7 million in Q1 2026, $275.4 million in Q4 2025, and $315.8 million in Q3 2025.